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occlusive cuff. The limbs were hyperperfused through arte-
rial access devices with a pump, producing a nonpulsatile
waveform at 200% to 300% of the mean arterial pressure
(MAP). This was performed intermittently in sessions of 24
to 36 hours and up to a maximum of 74 hours. The primary
end point was avoidance of major amputation. The second-
ary end points were the clinical improvements in rest pain,
ulcer healing, and claudication distance. The objective find-
ings include infrared thermography and ultrasound imag-
ing parameters of the limb.
Results: 39 of 40 connections developed flows 4 to 8
times those supplied to the limb by the normal cardiac
output. There was a progressive decrease in peripheral
resistance. All patients developed a pain-free, warm foot or
handwhilst on the pump in the short-term. In the longterm
at a mean of 22 months (12-54 months), eight of 20
patients (40%) had avoided major amputation and four
more had a delay in amputation of an average of 4 months.
The ankle-brachial index changed from 0.11  0.23 to
0.61 0.38 (P .05). Bleeding, infection, and removal of
the access systems and poor patient selection resulted in the
failures.
Conclusions: In selected cases major amputation may
be avoided by augmenting the collateral circulation of
ischemic limbs using an extracorporeal cardiac pump, oc-
cluding balloons and with an access system providing inter-
mittent pump connections.
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mance Goals: A Validation Study of Laser-Assisted
Angioplasty: A Safe and Effective Technique for the
Management of Critical Limb Ischemia
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Norfolk, VA
Objectives: In 2009 the Society for Vascular Surgery
(SVS) developed Objective Performance Goals (OPGs) to
assess the safety and efficacy of endovascular treatments of
critical limb ischemia (CLI). We evaluated Laser-assisted
angioplasty (LAA), using the OPGs
Methods: All patients that underwent LAA to treat
CLI between January 2006 and May 2010 were analyzed.
The 30 day safety endpoints of Major Adverse Cardiac
Event (MACE) (i.e. Postoperative Death (POD), Myocar-
dial Infarction (MI ) and Cerebrovascular Accident (CVA),
Amputation rate and Major Adverse Limb Event (MALE)
rate (i.e. thrombosis, thrombectomy, and bypass) were
calculated. The efficacy endpoints were calculated using
Kaplan-Meier life table analysis. These included MALE 
POD, Amputation Free Survival (AFS), and any Re-inter-
vention or above ankle Amputation and Stenosis /occlu-
sion (RAS) calculated at one year. Subsequently, a compar-
ison with the SVSOPGs was made using the student T test.
Results: : Laser assisted angioplasty was used to treat
82 limbs with CLI. The mean age was 72.8 years, with a
mean follow up of 19 months. Tissue loss and gangrene
were the most common indications, in 67 (81.2%) of the
limbs. Safety endpoints were: mortality rate 2.6%, MACE
rate 3.9%, amputation rate 2.4%, and MALE rate of 9.7%.
Efficacy endpoints were MALE  POD 84.1%, Amputa-
tion Free Survival 84.1%, and RAS 39%.Our study cohort
was compared to the SVS OPGs using the Student T test;
MACE 3.9% vs. 5.1% (P  .72), 30 day amputation rate
2.4% vs. 1.3% (P  .43), MALE 9.7% vs. 4.6% (P  .06).
One year outcomes: MALEPOD 84.1% vs. 76.9% (P 
.14), AFS 84.1% vs. 76.5% (P  .14), RAS 39% vs. 46.5%
(P  .21). No statistically significant difference was noted.
Conclusions: Our study demonstrates that the OPGs
are attainable in clinical practice. Moreover, LAAmeets the
safety and efficacy OPGs for endovascular treatment of
CLI.
Author Disclosures: S. S. Ahanchi: Nothing to disclose;
B. Almaroof: Nothing to disclose; J. A. Higgins: Nothing
to disclose; J. J. Kim: Nothing to disclose; J. M. Pan-
neton: Spectranetics, Speaker=s bureau; S. N. Steerman:
Nothing to disclose.
PS108.
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Objectives: Local vancomycin treatment has been
shown to decrease sternal wound complication rates.
Whether a similar effect can be achieved at other surgical
sites is unknown. This study investigates the effect of local
vancomycin on inguinal wound complication rates follow-
ing vascular procedures.
Methods: Retrospective analysis was performed on
646 patients who underwent open infra-inguinal and hy-
brid endovascular procedures between 2006 and 2011.
Patients received either pre-operative systemic antibiotics
alone (Group A) or in conjunction with intra-operative
wound application of vancomycin powder and irrigation
(Group B). Wound site infection and dehiscence over a
30-day period were recorded. Fisher exact test and multi-
variate regression analyses were performed.
Results: There were 424 patients in Group A and 222
patients in Group B. Both groups had similar demographics
and distribution of vascular procedures. There was no
significant difference in the 30-day incidence of superficial
and deep wound infections (OR: 0.72, P  .19) or dehis-
cence (OR: 1.2, P  .46) between the two groups after
JOURNAL OF VASCULAR SURGERY
June Supplement 201254S Abstracts
adjusting for type of operation, body mass index, chronic
renal dysfunction and presence of chronic lung disease.
Conclusions: In contrast to other surgical sites, local
vancomycin administration did not improve the rate of
short term inguinal wound complications following vascu-
lar procedures. A prospective study is needed to further
delineate the role of local vancomycin adjunct treatment on
inguinal wound outcomes.
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Anesthesia Type and Outcomes following Lower Ex-
tremity Amputations
Michael R. Buckley1, Thomas D. Conlee1, Jeanette An-
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dolph L. Geary1, Kimberley J. Hansen1, Noel Harrington2,
Matthew S. Edwards1. 1Wake Forest Medical Center De-
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Salem, NC; 2Wake Forest Medical Center Department of
Anesthesiology, Winston-Salem, NC; 3Wake Forest Medi-
cal School Department of Biostatistical Sciences, Winston-
Salem, NC
Objectives: The purpose of this study is to compare
types of anesthesia in major lower extremity amputations
(LEA) in order to determine whether one type is superior
to another in terms of morbidity and mortality.
Methods: Major LEAs performed between 2005 and
2008 were identified from the American College of Sur-
geons National Surgical Quality Improvement Program
database (ACS-NSQIP) using CPT codes. Anesthesia was
defined as general or regional (epidural, spinal or other
regional). Patient-level co-morbidities and characteristics,
as well as intraoperative and postoperative details were
examined. Complications were analyzed individually, and
in aggregate categories. Procedure-specific variables,
length of stay (LOS), and 30-day mortality were examined.
Characteristics and outcomes were described usingmean
SD or count (%) and associations with anesthesia type were
evaluated for statistical significance. Associations between
morbidity andmortality and anesthesia type were examined
using uni- and multivariable logistic and linear regression
techniques.
Results: 1,592 LEAs were identified for analysis. Of
these, general anesthesia was employed in 1294 (81%) of
these cases. Mean patient age was 68 14 years, 61% were
men, and 66% were white. Overall, the 30-day mortality
was 6.5% (104), any type morbidity occurred in 24.1%
(383), while the mean LOS was 5 (3, 7) days. There was no
statistical difference in the type of surgeon performing the
amputations (85% vascular surgeons overall) between the
types of anesthesia. No univariate differences were observed
by anesthesia type in terms of procedural specifics, LOS or
the occurrence of morbidity (individual or aggregate) or
mortality. Multivariate analyses also demonstrated no rela-
tionship between anesthesia type and the occurrence of
overall morbidity or mortality.
Conclusions: In contemporary surgical practice, based
on outcomes of morbidity and mortality, there appears to
be no difference in anesthesia type when major LEAs are
performed.
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Objectives: Femorofemoral crossover bypasses
(FFCB) are used in both patients with unilateral iliac artery
occlusive disease (IAOD) and in patients with aortoilliac
aneurysms (AIA) treated with an aorto-uni-iliac stentgraft.
The purpose of this study is to evaluate the durability and
effectiveness of a femorofemoral crossover bypass for pa-
tients with aneurysmal and stenotic arterial disease.
Methods: All patients treated with FFCB for aneurys-
mal or stenotic arterial disease from 2001 to 2011 in 2
Dutch tertiary vascular referral hospitals were included.
Data were retrospectively reviewed.
Results: Ninety-five patients were included. The AIA
group consisted of 48 patients (median age 78 years, IQR
72-84; 36 men) and the IAOD group consisted of 47
patients (median age 71, IQR 63-77; 35 men). Twenty-six
of 48 patients in the AIA group (54%) were treated for
ruptured aneurysms. In the IAOD group Fontaine classifi-
cation was as follows: II 60%, III 21% and IV 19%. Tradi-
tional cardiovascular risk factors were comparable between
both groups.Median follow-upwas 19months (IQR 1-41)
in the AIA group and 28months (IQR 14-50) in the IAOD
group. Primary patency after 2 years was 90% for the AIA
group and 79% for the IOAD group (P  .3). Secondary
patency rates were respectively 100% and 95% (P  .4).
Overall one-year mortality was in the AIA group 10% for
non-ruptured aneurysms and 54% for ruptured aneurysms
and was in the IAOD group 13%. In 6 AIA patients (13%)
bypass related complications were reported (5 stenoses/
occlusions requiring percutaneous transluminal angioplasty
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